Form 4: CalciMedica CEO Rachel Leheny Reports Future Stock Purchase Under 10b5-1 Plan

CalciMedica, Inc.'s Chief Executive Officer, Rachel Leheny, reported a planned acquisition of 2,500 shares of common stock at $2.47 per share, effective July 14, 2025, under a Rule 10b5-1 plan.

Summary

• Rachel Leheny, who serves as Chief Executive Officer, Director, and a 10% Owner of CalciMedica, Inc. (CALC), reported a transaction involving the company's common stock.
• The transaction entails the acquisition of 2,500 shares of CalciMedica Common Stock at a price of $2.47 per share.
• The reported transaction date is July 14, 2025, with the filing occurring on July 15, 2025.
• The shares were acquired indirectly by the Scheibler-Leheny Family Living Trust.
• This acquisition was executed pursuant to a Rule 10b5-1(c) plan, indicating a pre-arranged purchase strategy.
• Following this transaction, Rachel Leheny's total beneficial ownership in CalciMedica, Inc. amounts to 873,752 shares, which includes 130,926 direct shares and 742,826 indirect shares held through various entities such as the Scheibler-Leheny Family Living Trust, spouse, and Valence Investments SPV IV, V, and VI, LLCs.

Sentiment

Score: 7

Explanation: The acquisition of shares by the CEO, even if pre-planned under a 10b5-1 plan, generally indicates management's confidence in the company's valuation and future prospects. The future transaction date is unusual but does not negate the positive signal of insider buying.

Positives

• The Chief Executive Officer, Rachel Leheny, is acquiring additional shares, which typically signals confidence in the company's future prospects and valuation.
• The purchase was made at a specific price of $2.47 per share, providing a clear valuation point for the insider's investment.

Negatives

• The transaction date of July 14, 2025, is in the future, which is unusual for a Form 4 filing that typically reports past transactions, indicating a pre-planned future event rather than an immediate, reactive show of confidence.

Future Outlook

NA

Industry Context

NA

Related Party Transactions

• Rachel Leheny, as CEO, Director, and 10% owner, acquired 2,500 shares of CalciMedica common stock indirectly through the Scheibler-Leheny Family Living Trust, which constitutes a related party transaction.

Stakeholder Impact

• Shareholders may view the CEO's share purchase as a positive signal of confidence in the company's future, potentially influencing investor sentiment.
• The transaction itself does not directly impact employees, customers, suppliers, or creditors beyond potential indirect effects on company valuation and stability.

Key Dates

Recommendation

Keywords

CalciMedica, CALC, SEC Form 4, Insider Trading, Stock Purchase, CEO, Rachel Leheny, Beneficial Ownership, Rule 10b5-1, Equity Acquisition